Panavance Therapeutics, Inc.
- | Biotech or pharma, therapeutic R&D
Panavance Therapeutics Inc. is a privately held, clinical-stage oncology co. developing GP-2250, a small molecule with a novel MOA that targets cancer's energy metabolism & NfKB. GP-2250 is in a multi-center Phase 1 clinical trial in pancreatic cancer.
Address
BerwynPennsylvania
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}